Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency

Journal of the American Society of Nephrology

Volumn 18, Issue 6, 2007, Pages 1889-1898

  Fan, Fan Hou ^a   Xie, Di ^a   Zhang, Xun ^a   Ping, Yan Chen ^b   Wei, Ru Zhang ^a   Liang, Min ^a   Zhi, Jian Guo ^a   Jian, Ping Jiang ^a  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; CREATININE; DIURETIC AGENT; LOSARTAN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DEATH; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FATALITY; FEMALE; FOLLOW UP; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 34249897487     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006121372     Document Type: Article

References (41)

1. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P; The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939-945, 1996
2. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
4. Mann JF, McClellan WM, Kunz R, Ritz E: Progression of renal disease: Can we forget about inhibition of the renin-angiotensin system? Nephrol Dial Transplant 21: 2348-2351, 2006
5. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354: 131-140, 2006
6. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135: 73-87, 2001 [published erratum appears in Ann Intern Med 137: 299, 2002]
7. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition - A patient-level meta-analysis. Ann Intern Med 139: 244-252, 2003
8. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int 67: 799-812, 2005
9. Ruggenenti P: Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies. Semin Nephrol 24: 158-167, 2004
10. Peters H, Border WA, Noble NA: Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54: 1570-1580, 1998
11. Fogo AB: Progression and potential regression of glomerulosclerosis. Kidney Int 59: 804-819, 2001
12. Laverman GD, Henning RH, de Jong PE, Navis G, de Zeeuw D: Optimal antiproteinuric dose of losartan in non-diabetic patients with nephrotic range proteinuria. Am J Kidney Dis 38: 1381-1384, 2001
13. Aranda P, Segura J, Ruilope LM, Aranda FJ, Frutos MA, Lopez V, Lopez de Novales E: Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 46: 1074-1079, 2005
14. Weinberg MS, Weinberg AJ, Zappe DH: Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: Rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. J Renin Angiotensin Aldosterone Syst 1: 217-233, 2000
15. Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH: Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 17: 1413-1418, 2002
16. Haas M, Leko-Mohr Z, Erler C, Mayer G: Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy. Am J Kidney Dis 40: 458-463, 2002
17. Ruggenenti P, Mise N, Pisoni R, Arnoldi F, Pezzotta A, Perna A, Cattaneo D, Remuzzi G: Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 107: 586-592, 2003
18. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106: 672-678, 2002
19. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361: 117-124, 2003 [published erratum appears in Lancet 361: 1230, 2003]
20. Levey AS: Clinical evaluation of renal function. In: Primer on Kidney Diseases, 2nd Ed., edited by Greenberg A, San Diego, Academic Press, 1998, pp 20-26
21. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS: A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 25: 1345-1350, 1995
22. Bos H, Andersen S, Rossing P, De Zeeuw D, Parving HH, De Jong PE, Navis G: Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int 57[Suppl 75]: S32-S37, 2000
23. Levey AS, Greene T, Kusek JW, Beck GJ: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 11: 155A, 2000
24. Adler SG. Quantitative and qualitative measurement of urinary protein. In: Textbook of Nephrology, 4th Ed., edited by Massry SG, Glassock RJ, Philadelphia, Lippincott Williams & Wilkins, 2001, pp 1784-1786
25. Zhang GH, Hou FF, Zhang X, Liu QF: Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L [in Chinese]? Zhonghua Nei Ke Za Zhi 44: 592-596, 2005
26. Dialysis and Transplantation Registration Group, Chinese Society of Nephrology: The report about the registration of dialysis and transplantation in China 1999. Chin J Nephrol 17: 77-78, 2001
27. Pisoni R, Ruggenenti P, Sangalli F, Lepre MS, Remuzzi A, Remuzzi G: Effect of high dose ramipril with or without indomethacin on glomerular selectivity. Kidney Int 62: 1010-1019, 2002
28. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C: Additional antiproteinuric effect of ultrahigh dose candesartan: A double-blind, randomized, prospective study. J Am Soc Nephrol 16: 3038-3045, 2005
29. Palla R, Panichi V, Finato V, Parrini M, Andreini B, Bianchi AM, Giovannini L, Migliori M, Bertelli AA: Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res 14: 35-43, 1994
30. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D: Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62: 1020-1025, 2002
31. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 334: 13-18, 1996
32. Sheinfeld GR, Bakris GL: Benefits of combination angio-tensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens 12: 80S-85S, 1999
33. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57: 601-606, 2000
34. Jacobsen P, Andersen S, Jensen BR, Parving HH: Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 14: 992-999, 2003
35. Navis G, Kramer AB, de Jong PE: High-dose ACE inhibition: Can it improve renoprotection? Am J Kidney Dis 40: 664-666, 2002
36. Ruggenenti P, Perna A, Remuzzi G; GISEN Group Investigators: Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 63: 2254-2261, 2003
37. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001
38. Miyata T, van Ypersele de Strihou C: Renoprotection of angiotensin receptor blockers: Beyond blood pressure lowering. Nephrol Dial Transplant 21:846-849, 2006
39. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ: Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 353: 2008-2013, 1999
40. Lufft V, Kliem V, Hamkens A, Bleck JS, Eisenberger U, Petersen R, Ehlerding G, Maschek H, Pichlmayr R, Brunkhorst R: Antiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage. Clin Transplant 12: 409-415, 1998
41. Hansson L, Hedner T, Dahlof B: Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1: 113-119, 1992